Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program
Authors:
- 24 May 2019
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 17 (9) , 1470-1477
Abstract
No abstract availableKeywords
Funding Information
- F. Hoffmann-La Roche
This publication has 13 references indexed in Scilit:
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsNew England Journal of Medicine, 2017
- Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc AnalysesTH Open, 2017
- Safety update on the use of recombinant activated factor VII in approved indicationsBlood Reviews, 2015
- Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg−1) rFVIIa doses across clinical trials and registriesHaemophilia, 2013
- Guidelines for the management of hemophiliaHaemophilia, 2012
- The need for speed in the management of haemophilia patients with inhibitorsHaemophilia, 2010
- Recombinant coagulation factor VIIa – from molecular to clinical aspects of a versatile haemostatic agentThrombosis Research, 2010
- Clinical outcome of moderate haemophilia compared with severe and mild haemophiliaHaemophilia, 2009
- Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitorsHaemophilia, 2008
- Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitorsJournal of Thrombosis and Haemostasis, 2004